TY - JOUR
T1 - Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections
AU - Alabiad, Chrisfouad R.
AU - Miller, Darlene
AU - Schiffman, Joyce C.
AU - Davis, Janet L.
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Publication of this article was supported by an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc , New York, New York; and Core Grant P30EY014801 from the National Eye Institute, National Institutes of Health , Bethesda, Maryland. Dr Davis has a consulting arrangement with Centocor and receives grant support from Centocor and Novartis . The other authors have no proprietary interests or financial disclosures. Involved in Design and conduct of study (C.R.A., D.M., J.L.D.); Collection, management, analysis, and interpretation of data (C.R.A., D.M., J.C.S., J.L.D.); and Preparation, review, and approval of manuscript (C.R.A., D.M., J.C.S., J.L.D.). The Human Subjects Research Committee at the University of Miami, Miller School of Medicine approved the conduct of this prospective study. Patient information was handled in accordance to Health Insurance Portability and Accountability guidelines.
PY - 2011/12
Y1 - 2011/12
N2 - Purpose: To identify the resistance profiles of conjunctival and nasal bacterial isolates in patients undergoing intravitreal injections and to determine if frequent exposures to topical fluoroquinolones increased antimicrobial resistance among these organisms. Design: Prospective cohort study. Methods: Patients undergoing intravitreal injection at our institution were enrolled in this study. The conjunctiva and nares of both sides of the patient's face were swabbed and cultured before antiseptic preparation for intravitreal injection. At the time of the study, all patients received 3 days of moxifloxacin eye drops after each intravitreal injection as prophylaxis against endophthalmitis. Resistance to antimicrobials was analyzed using the chi-square test and t test. Results: Two hundred eight conjunctival and nasal specimens were cultured from 104 patients. Forty-two (45%) of 93 patients had at least 1 fluoroquinolone-resistant organism in the nose or conjunctiva. Twelve (48%) of 25 patients with no previous injections had at least 1 resistant organism; 14 (45%) of 31 patients with 1 to 4 previous injections had at least 1 resistant organism; 8 (33%) of 24 patients with 5 to 9 previous injections had at least 1 resistant organism; and 8 (62%) of 13 patients with 10 or more previous injections had at least 1 resistant organism (P =.88; chi-square test, linear by linear association). Conclusions: In this small study, there was no correlation between the number of exposures to topical fluoroquinolones and resistance to fluoroquinolones in nasal and conjunctival flora, but there was a high prevalence of fluoroquinolone resistance among all patient groups.
AB - Purpose: To identify the resistance profiles of conjunctival and nasal bacterial isolates in patients undergoing intravitreal injections and to determine if frequent exposures to topical fluoroquinolones increased antimicrobial resistance among these organisms. Design: Prospective cohort study. Methods: Patients undergoing intravitreal injection at our institution were enrolled in this study. The conjunctiva and nares of both sides of the patient's face were swabbed and cultured before antiseptic preparation for intravitreal injection. At the time of the study, all patients received 3 days of moxifloxacin eye drops after each intravitreal injection as prophylaxis against endophthalmitis. Resistance to antimicrobials was analyzed using the chi-square test and t test. Results: Two hundred eight conjunctival and nasal specimens were cultured from 104 patients. Forty-two (45%) of 93 patients had at least 1 fluoroquinolone-resistant organism in the nose or conjunctiva. Twelve (48%) of 25 patients with no previous injections had at least 1 resistant organism; 14 (45%) of 31 patients with 1 to 4 previous injections had at least 1 resistant organism; 8 (33%) of 24 patients with 5 to 9 previous injections had at least 1 resistant organism; and 8 (62%) of 13 patients with 10 or more previous injections had at least 1 resistant organism (P =.88; chi-square test, linear by linear association). Conclusions: In this small study, there was no correlation between the number of exposures to topical fluoroquinolones and resistance to fluoroquinolones in nasal and conjunctival flora, but there was a high prevalence of fluoroquinolone resistance among all patient groups.
UR - http://www.scopus.com/inward/record.url?scp=81855218675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81855218675&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2011.05.026
DO - 10.1016/j.ajo.2011.05.026
M3 - Article
C2 - 21861973
AN - SCOPUS:81855218675
VL - 152
SP - 999-1004.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 6
ER -